Axovant Sciences Company Profile (NYSE:AXON)

About Axovant Sciences (NYSE:AXON)

Axovant Sciences logoAxovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer's disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company's pipeline also includes RVT-103 and RVT-104.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSE:AXON
  • CUSIP: N/A
  • Web: www.axovant.com
Capitalization:
  • Market Cap: $2.26342 billion
  • Outstanding Shares: 106,400,000
Average Prices:
  • 50 Day Moving Avg: $22.68
  • 200 Day Moving Avg: $19.46
  • 52 Week Range: $11.01 - $26.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.98
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.92 per share
  • Price / Book: 10.94
Profitability:
  • EBIDTA: ($207,250,000.00)
  • Return on Equity: -120.65%
  • Return on Assets: -87.29%
Debt:
  • Debt-to-Equity Ratio: 0.25%
  • Current Ratio: 6.01%
  • Quick Ratio: 6.01%
Misc:
  • Average Volume: 518,642 shs.
  • Beta: 0.41
  • Short Ratio: 7.32
 

Frequently Asked Questions for Axovant Sciences (NYSE:AXON)

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd. (NYSE:AXON) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.12. View Axovant Sciences' Earnings History.

When will Axovant Sciences make its next earnings announcement?

Axovant Sciences is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Axovant Sciences.

Where is Axovant Sciences' stock going? Where will Axovant Sciences' stock price be in 2017?

10 analysts have issued 12-month price targets for Axovant Sciences' shares. Their forecasts range from $7.50 to $40.00. On average, they expect Axovant Sciences' share price to reach $29.17 in the next year. View Analyst Ratings for Axovant Sciences.

What are analysts saying about Axovant Sciences stock?

Here are some recent quotes from research analysts about Axovant Sciences stock:

  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (7/11/2017)
  • 2. Piper Jaffray Companies analysts commented, "We see these results as mixed but positive for the company's first foray into this under-studied disease. First off, nelo' did appear safe/well tolerated, which was a non-zero risk in this population. In addition, the study suggested some benefit on ADL and motor function ' not exactly what we were expecting, but if replicated could address a key unmet need in DLB especially. We didn't yet see improvement on visual hallucinations but longer dosing in more patients may be helpful here. We'll await full results around mid'17, and remain optimistic these results and/or the DLB-RBD study will inform a Phase III program for nelo' in at least one LBD symptom complex. For now, nelo' is upside to our valuation and we remain focused on the pivotal programs for RVT-101 in AD and DLB." (2/13/2017)

Who are some of Axovant Sciences' key competitors?

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:

  • Marion McCourt, President, Chief Operating Officer
  • David T. Hung M.D., Chief Executive Officer, Director
  • Gregory M. Weinhoff M.D., Chief Financial Officer
  • Vivek Ramaswamy, Director, Chief Executive Officer - Roivant Sciences
  • Mark Altmeyer, President of Axovant Sciences GmbH and Chief Commercial Officer
  • Eric Floyd Ph.D., Senior Vice President - Regulatory Affairs
  • Ilise Lombardo M.D., Senior Vice President - Clinical Research
  • Thomas Templeman Ph.D., Senior Vice President - Pharmaceutical Operations and Quality Assurance
  • Mark Wadley, Senior Vice President, US Business
  • Samina Bari, Vice President - Corporate Communications

When did Axovant Sciences IPO?

(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who owns Axovant Sciences stock?

Axovant Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (6.74%), Capital Research Global Investors (3.25%), Janus Henderson Group PLC (1.94%), Franklin Resources Inc. (1.36%), State Street Corp (0.51%) and PointState Capital LP (0.33%). Company insiders that own Axovant Sciences stock include David Hung, Mark Altmeyer and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.

Who sold Axovant Sciences stock? Who is selling Axovant Sciences stock?

Axovant Sciences' stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP, Franklin Resources Inc., VHCP Management II LLC, Artal Group S.A., Candriam Luxembourg S.C.A., Nationwide Fund Advisors, Ameriprise Financial Inc. and Strs Ohio. View Insider Buying and Selling for Axovant Sciences.

Who bought Axovant Sciences stock? Who is buying Axovant Sciences stock?

Axovant Sciences' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Janus Henderson Group PLC, Capital Research Global Investors, State Street Corp, Ratan Capital Management LP, OxFORD Asset Management LLP, Prudential Financial Inc. and Federated Investors Inc. PA. Company insiders that have bought Axovant Sciences stock in the last two years include David Hung, Mark Altmeyer and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences.

How do I buy Axovant Sciences stock?

Shares of Axovant Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of Axovant Sciences stock can currently be purchased for approximately $21.01.


MarketBeat Community Rating for Axovant Sciences (NYSE AXON)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Axovant Sciences (NYSE:AXON) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $29.17 (38.82% upside)

Analysts' Ratings History for Axovant Sciences (NYSE:AXON)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$40.00LowView Rating Details
6/21/2017Cowen and CompanyReiterated RatingOutperform$30.00MediumView Rating Details
6/14/2017CIBCBoost Price TargetOutperform -> Outperform$26.00 -> $30.00HighView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$26.00 -> $30.00MediumView Rating Details
4/12/2017Piper Jaffray CompaniesReiterated RatingOverweight$32.00LowView Rating Details
2/14/2017HC WainwrightSet Price TargetBuy$35.00N/AView Rating Details
12/20/2016Robert W. BairdReiterated RatingPositive$29.00N/AView Rating Details
12/20/2016LaidlawInitiated CoverageSell$7.50N/AView Rating Details
11/8/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Evercore ISIReiterated RatingBuy$29.00N/AView Rating Details
6/30/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
2/3/2016Chardan CapitalReiterated RatingSell$8.00N/AView Rating Details
(Data available from 8/19/2015 forward)

Earnings

Earnings History for Axovant Sciences (NYSE:AXON)
Earnings by Quarter for Axovant Sciences (NYSE:AXON)
Earnings History by Quarter for Axovant Sciences (NYSE AXON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.58)N/AView Earnings Details
10/23/2017N/AView Earnings Details
8/7/2017Q1 2018($0.53)($0.65)ViewN/AView Earnings Details
6/13/20173/31/2017($0.51)($0.53)ViewN/AView Earnings Details
2/14/2017Q3($0.45)($0.48)ViewN/AView Earnings Details
8/15/2016Q1($0.36)($0.38)ViewN/AView Earnings Details
6/6/2016Q4 2016($0.30)($0.30)ViewN/AView Earnings Details
2/9/2016Q315($0.15)($0.64)ViewN/AView Earnings Details
11/2/2015Q215($0.24)($0.12)ViewN/AView Earnings Details
8/11/2015Q115($0.10)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Axovant Sciences (NYSE:AXON)
Current Year EPS Consensus Estimate: $-2.32 EPS
Next Year EPS Consensus Estimate: $-3.01 EPS

Dividends

Dividend History for Axovant Sciences (NYSE:AXON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Axovant Sciences (NYSE:AXON)
Insider Ownership Percentage: 72.50%
Institutional Ownership Percentage: 94.54%
Insider Trades by Quarter for Axovant Sciences (NYSE:AXON)
Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)
Insider Trades by Quarter for Axovant Sciences (NYSE:AXON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017David HungInsiderBuy539,375$18.54$10,000,012.50View SEC Filing  
4/17/2017W Anthony VernonDirectorBuy53,937$18.54$999,991.98View SEC Filing  
3/10/2016Mark AltmeyerInsiderBuy2,300$11.14$25,622.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Axovant Sciences (NYSE:AXON)
Latest Headlines for Axovant Sciences (NYSE:AXON)
Source:
DateHeadline
americanbankingnews.com logoAxovant Sciences Target of Unusually High Options Trading (AXON)
www.americanbankingnews.com - August 19 at 1:32 AM
nasdaq.com logoOptions Traders Expect Huge Moves in Axovant Sciences (AXON) Stock - Nasdaq
www.nasdaq.com - August 18 at 9:24 PM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
finance.yahoo.com - August 18 at 4:23 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
finance.yahoo.com - August 10 at 4:24 PM
finance.yahoo.com logoRoivant's Billion-Dollar Haul Shouldn't Buy Off Skepticism
finance.yahoo.com - August 10 at 4:24 PM
finance.yahoo.com logo[$$] SoftBank Leads $1.1 Billion Investment in Roivant Sciences
finance.yahoo.com - August 9 at 9:31 PM
finance.yahoo.com logoBiotech Wunderkind Raises $1.1 Billion To Fund Pharma Startups
finance.yahoo.com - August 9 at 4:28 PM
finance.yahoo.com logoA 32-year-old biotech CEO just raised $1.1 billion from SoftBank to give old drugs new life
finance.yahoo.com - August 9 at 4:28 PM
americanbankingnews.com logoAxovant Sciences Ltd. (NYSE:AXON) Posts Earnings Results, Misses Estimates By $0.12 EPS
www.americanbankingnews.com - August 8 at 10:51 AM
finance.yahoo.com logoAxovant Announces Fiscal First Quarter Financial Results and Corporate Updates
finance.yahoo.com - August 7 at 5:03 PM
finance.yahoo.com logoAxovant reports 1Q loss
finance.yahoo.com - August 7 at 5:03 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) to Release Earnings on Monday
www.americanbankingnews.com - August 7 at 7:50 AM
americanbankingnews.com logoAxovant Sciences Ltd. (NYSE:AXON) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 4 at 8:52 AM
americanbankingnews.com logo Analysts Expect Axovant Sciences Ltd. (AXON) to Announce -$0.52 Earnings Per Share
www.americanbankingnews.com - August 3 at 8:08 AM
finance.yahoo.com logoWill Axovant Catch Lightning in a Bottle With Its Alzheimer's Drug?
finance.yahoo.com - July 26 at 4:53 PM
americanbankingnews.com logo-$0.54 Earnings Per Share Expected for Axovant Sciences Ltd. (AXON) This Quarter
www.americanbankingnews.com - July 11 at 10:16 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 11 at 5:26 PM
americanbankingnews.com logoAxovant Sciences Ltd. (NYSE:AXON) Coverage Initiated at Jefferies Group LLC
www.americanbankingnews.com - July 10 at 5:26 PM
finance.yahoo.com logoAxovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International Conference
finance.yahoo.com - July 10 at 4:18 PM
finance.yahoo.com logoDermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman
finance.yahoo.com - July 10 at 4:18 PM
americanbankingnews.com logoAxovant Sciences Ltd. (NYSE:AXON) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 10 at 8:57 AM
bloomberg.com logoBiotech's IPO Uptick Is Nothing to Fear
www.bloomberg.com - July 8 at 8:58 PM
americanbankingnews.com logoBidaskClub Downgrades Axovant Sciences Ltd. (NYSE:AXON) to Hold
www.americanbankingnews.com - July 8 at 1:02 PM
prnewswire.com logoBiotech Stock Performance Review -- Vertex Pharma, VIVUS, Xbiotech, and Axovant Sciences - PR Newswire (press release)
www.prnewswire.com - June 30 at 10:10 PM
finance.yahoo.com logoEarnings Review and Free Research Report: Axovant Sciences Reported Lower than Expected Earnings
finance.yahoo.com - June 29 at 5:21 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - June 25 at 1:52 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Lifted to Buy at BidaskClub
www.americanbankingnews.com - June 23 at 11:28 PM
finance.yahoo.com logoFeatured Company News - Juno Therapeutics Shared Updated Data for TRANSCEND NHL 001 Clinical Trial at the IMCL Conference in Switzerland
finance.yahoo.com - June 20 at 4:27 PM
finance.yahoo.com logoFDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies
finance.yahoo.com - June 19 at 9:44 AM
americanbankingnews.com logo Brokerages Anticipate Axovant Sciences Ltd. (AXON) Will Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - June 15 at 10:20 PM
finance.yahoo.com logoRigorous Trial Design, Nice Risk/Reward Keep Analyst Anxious For Avoxant's Phase 3 MINDSET Data
finance.yahoo.com - June 14 at 8:57 PM
americanbankingnews.com logoOppenheimer Holdings, Inc. Boosts Axovant Sciences Ltd. (AXON) Price Target to $30.00
www.americanbankingnews.com - June 14 at 1:00 PM
americanbankingnews.com logoCIBC Reaffirms "Outperform" Rating for Axovant Sciences Ltd. (AXON)
www.americanbankingnews.com - June 14 at 12:28 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Given "Outperform" Rating at Cowen and Company
www.americanbankingnews.com - June 13 at 7:16 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - June 13 at 2:26 PM
finance.yahoo.com logoAxovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates
finance.yahoo.com - June 13 at 1:17 PM
finance.yahoo.com logoAxovant reports 4Q loss
finance.yahoo.com - June 13 at 1:17 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 13 at 8:58 AM
americanbankingnews.com logoJefferies Group LLC Reiterates Buy Rating for Axovant Sciences Ltd (AXON)
www.americanbankingnews.com - June 9 at 5:08 PM
streetinsider.com logoAxovant Sciences (AXON) Appoints Patrick Machado to Board - StreetInsider.com
www.streetinsider.com - June 7 at 8:37 AM
finance.yahoo.com logoAxovant Announces Changes to Board of Directors
finance.yahoo.com - June 6 at 3:56 PM
finance.yahoo.com logoAxovant Strengthens Executive Team with Key Management Appointments
finance.yahoo.com - June 6 at 3:56 PM
nasdaq.com logoNotable Thursday Option Activity: CBI, AXON, ALRM - Nasdaq
www.nasdaq.com - June 1 at 9:07 PM
nasdaq.com logoCommit To Purchase Axovant Sciences At $12.50, Earn 103.3% Annualized Using Options - Nasdaq
www.nasdaq.com - May 26 at 4:05 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 9:24 AM
americanbankingnews.com logo-$0.51 EPS Expected for Axovant Sciences Ltd (AXON) This Quarter
www.americanbankingnews.com - April 28 at 11:13 AM
seekingalpha.com logoInsider Transactions Weekly Newsletter
seekingalpha.com - April 26 at 4:05 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 24 at 11:36 AM
rttnews.com logoCompany Spotlight: Axovant Sciences
www.rttnews.com - April 22 at 10:21 AM
nasdaq.com logoCompany Spotlight: Axovant Sciences - Nasdaq
www.nasdaq.com - April 21 at 3:50 PM

Social

Chart

Axovant Sciences (AXON) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by MarketBeat.com Staff